Salim Syed
Stock Analyst at Mizuho
(1.94)
# 3,057
Out of 4,902 analysts
81
Total ratings
36.92%
Success rate
-7.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.05 | +582.93% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $39.21 | +114.23% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $128.07 | +31.96% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $297.87 | -6.00% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $108.77 | +7.57% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $7.97 | +176.04% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $37.45 | +335.25% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $9.45 | +90.48% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $22.49 | +51.18% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $55.12 | +79.61% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $46.75 | +13.37% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $0.11 | +5,135.60% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $0.91 | +2,201.62% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $19.12 | +88.33% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.05
Upside: +582.93%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $39.21
Upside: +114.23%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $128.07
Upside: +31.96%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $297.87
Upside: -6.00%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $108.77
Upside: +7.57%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $7.97
Upside: +176.04%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $37.45
Upside: +335.25%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $9.45
Upside: +90.48%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $22.49
Upside: +51.18%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $55.12
Upside: +79.61%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $46.75
Upside: +13.37%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $0.11
Upside: +5,135.60%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $0.91
Upside: +2,201.62%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $19.12
Upside: +88.33%